FDLS - ETF AI Analysis
Top Page
Inspire Fidelis Multi Factor ETF (FDLS)
Rating:68Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and solid momentum over the last few months, which suggests its strategy has been working well in the current market.
Leading Holdings Showing Strength
Many of the top 10 stocks, especially in energy, healthcare, and materials, have delivered strong year-to-date performance, helping support the fund’s overall returns.
Broad Sector Diversification
The fund spreads its investments across many sectors, including technology, financials, industrials, health care, and energy, which helps reduce the impact if any single industry struggles.
Negative Factors
High Expense Ratio
The ETF’s fee is on the higher side compared with many broad market index funds, which can slightly reduce the net return investors receive over time.
Heavy U.S. Concentration
With almost all assets in U.S. companies and very little exposure to other countries, the fund is heavily tied to the health of the U.S. market and economy.
Some Lagging Top Holding
At least one of the largest positions has shown weak performance this year, which can drag on the fund if that stock does not improve.
FDLS vs. SPDR S&P 500 ETF (SPY)
AUM238.65M
RegionNorth America
Expense Ratio0.66%
Beta1.04
IssuerInspire
Inception DateAug 23, 2022
Dividend Yield0.8%
Asset ClassEquity
Index TrackedWI Fidelis Multi-Cap, Multi-Factor Index - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume27,396
30 Day Avg. Volume36,891
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
50.84Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering101
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FDLS Summary
FDLS, the Inspire Fidelis Multi Factor ETF, tracks the WI Fidelis Multi-Cap, Multi-Factor Index and aims to give broad exposure to the U.S. stock market while following values-based (ethical) guidelines. It mixes many types of companies by size and industry, with a tilt toward areas like technology, financials, and energy. Well-known names in the fund include Valero Energy and CF Industries. Someone might invest in FDLS for diversified growth across many sectors while aligning with their personal values. A key risk is that it can rise or fall with the overall stock market, and it has a relatively heavy tilt toward U.S. stocks.
How much will it cost me?The Inspire Fidelis Multi Factor ETF (FDLS) has an expense ratio of 0.69%, which means you’ll pay $6.90 per year for every $1,000 invested. This is higher than average because it is actively managed, using a sophisticated multi-factor strategy to optimize returns and align with ethical investing principles.
What would affect this ETF?The Inspire Fidelis Multi Factor ETF (FDLS) could benefit from strong performance in the technology and industrials sectors, which make up a significant portion of its holdings, as well as continued interest in values-based investing. However, it may face challenges from economic slowdowns or rising interest rates, which could negatively impact smaller companies and growth-oriented investments. Additionally, its focus on U.S. markets means it is sensitive to domestic economic and regulatory changes.
FDLS Top 10 Holdings
FDLS is leaning heavily into U.S. energy and health care names, with refiners like Par Pacific, HF Sinclair, and Valero acting as key engines for the fund’s recent upswing as they continue to rise on solid cash flows and improving sentiment. PACS Group and Aveanna add a health care tilt, showing steady-to-strong momentum but weighed down by leverage and profitability concerns. EverQuote’s mixed path, with strong recent bursts but a weaker year-to-date trend, keeps it from fully pulling its weight. Overall, the fund’s story is a U.S.-centric, factor-driven bet on cyclical energy strength and selective health care growth.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Par Pacific Holdings | 1.58% | $3.67M | $4.31B | 171.44% | 67 Neutral | |
| Bausch Health Companies | 1.42% | $3.30M | $2.57B | 21.11% | 59 Neutral | |
| Quad/Graphics | 1.38% | $3.20M | $535.08M | 82.97% | 52 Neutral | |
| HF Sinclair Corporation | 1.33% | $3.09M | $16.26B | 102.49% | 68 Neutral | |
| Columbus Mckinnon | 1.32% | $3.08M | $553.33M | 46.33% | 72 Outperform | |
| Valero Energy | 1.27% | $2.95M | $90.09B | 127.74% | 69 Neutral | |
| Ooma | 1.21% | $2.83M | $598.13M | 88.92% | 62 Neutral | |
| Ironwood Pharma | 1.21% | $2.81M | $696.31M | 489.33% | 54 Neutral | |
| Slide Insurance Holdings, Inc. | 1.20% | $2.80M | $2.33B | 11.68% | 73 Outperform | |
| Donnelley Financial Solutions | 1.20% | $2.80M | $1.16B | -6.72% | 64 Neutral |
FDLS Technical Analysis
Positive
―
Price Trends
41.65
Positive
40.37
Positive
38.42
Positive
Market Momentum
0.32
Negative
57.73
Neutral
75.64
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FDLS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 42.32, equal to the 50-day MA of 41.65, and equal to the 200-day MA of 38.42, indicating a bullish trend. The MACD of 0.32 indicates Negative momentum. The RSI at 57.73 is Neutral, neither overbought nor oversold. The STOCH value of 75.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FDLS.
FDLS Peer Comparison
Comparison Results
Performance Comparison
FDLS
Inspire Fidelis Multi Factor ETF
42.81
10.55
32.70%
HLAL
Wahed FTSE USA Shariah ETF
―
―
―
VFMF
Vanguard U.S. Multifactor ETF
―
―
―
AUSF
Global X Adaptive U.S. Factor ETF
―
―
―
FDMO
Fidelity Momentum Factor ETF
―
―
―
BGDV
Bahl & Gaynor Dividend ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents